Primary Care Reports – October 1, 2004

October 1, 2004

• Pharmacology Watch: Linking COX-2 Inhibitors and Cardiovascular Event Risk

  A new, and as of yet unpublished study, has raised increased concern about the relationship between rofecoxib (Vioxx), Mercks blockbuster COX-2 inhibitor, and cardiovascular events.

  Read more about Pharmacology Watch: Linking COX-2 Inhibitors and Cardiovascular Event Risk - Primary Care Reports – October 1, 2004

• Clinical Briefs in Primary Care Supplement

  Read more about Clinical Briefs in Primary Care Supplement - Primary Care Reports – October 1, 2004